Abstract
BackgroundRomiplostim is a new second-generation thrombopoietic agent that stimulates thrombopoietin receptors and platelet production.PurposeTo evaluate the efficacy and safety of romiplostim in a splenectomised man with idiopathic thrombocytopenic purpura (ITP)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
